Protein based drugs, such as antibodies, are made via the classical dogma: from DNA via RNA to our Protein of Interest (POI). IC-PCS starts from DNA and via a coupled in-vitro transcription and translation step we transcribe DNA to RNA and then translate RNA to our POI.
Traditionally living cells are recruited to make our POI, and though this is still the industrial standard in many fields of biotechnology and pharmaceutical companies, the process is lengthy and not well suited for screening purposes. One huge disadvantage is the lengthy production time (the up-stream process) and the protein purification steps that follow (the down-stream process). You can read more background information here.
In-vitro translation/transcription is also referred to as Cell Free Protein Synthesis or CFPS for good reason: the substance of formally living cells can be used to synthesis proteins. CFPS is rapid, not dependent on maintaining cells, more robust and reproducible, so ideal for screening purposes if used well aligned screening assays. CFPS for production of pharmaceutical proteins has entered the market, however very few companies are currently using this disruptive technology for production purposes.
In our CFPS-C&R module we merge the protein production phase and the protein purification phase into one simple step, we can release our pure POI into the right formulation for further testing within hours from adding our DNA to a functional protein drug formulation. Another groundbreaking aspect is the Process Analytical Technology build into the module: SPR for protein quantification and Time Gated Raman Spectroscopy for evaluation of our POI and the final formulation. Now we can harvest our product or we can escort our POI to the next modules (here and here).
Concluding, we can make from DNA a drug in a day instead of weeks or months and make exactly the same high-quality product every time.
Module status: prototype.